FILAVAC VHD K C+V SUSPENSION FOR INJECTION FOR RABBITS

Authorised

- Rabbit haemorrhagic disease virus, type 1, strain IM.507.SC.2011, Inactivated
- Rabbit haemorrhagic disease virus, type 2, strain LP.SV.2012, Inactivated

Product identification

Medicine name:
FILAVAC VHD K C+V SUSPENSION FOR INJECTION FOR RABBITS

Active substance:
Rabbit haemorrhagic disease virus, type 1, strain IM.507.SC.2011, Inactivated

Rabbit haemorrhagic disease virus, type 2, strain LP.SV.2012, Inactivated

Target species:
Rabbit

Route of administration:
Subcutaneous use

Product details

Active substance and strength:
Rabbit haemorrhagic disease virus, type 1, strain IM.507.SC.2011, Inactivated
1.00 90% protective dose / 1.00 Dose

Rabbit haemorrhagic disease virus, type 2, strain LP.SV.2012, Inactivated
1.00 90% protective dose / 1.00 Dose

Pharmaceutical form:
Suspension for injection

Withdrawal period by route of administration:
Subcutaneous use:

- **Rabbit**
  - All relevant tissues. 0 day

Anatomical therapeutic chemical veterinary (ATCvet) codes:
QI08AA01

Legal status of supply:
Veterinary medicinal product subject to veterinary prescription

Authorisation status:
Valid

Authorised in:
Luxembourg

Package description:
Available only in French
Available only in French
Available only in French
Available only in French
Available only in French
Available only in French
Available only in French

Additional information

Entitlement type:
Marketing Authorisation

Legal basis of product authorisation:
Full application - New active substance (Article 12(3) of Directive No 2001/82/EC)

Marketing authorisation holder:
Filavie

Marketing authorisation date:
10/05/2017

Manufacturing sites for batch release:
Filavie

Responsible authority:
Ministry Of Health And Social Security

Authorisation number:
V 330/09/03/1714

Date of authorisation status change:
10/05/2017

Reference member state:
France

Procedure number:
FR/V/0315/001

Concerned member states:
Austria Belgium Czechia Denmark Finland Germany Hungary Italy Luxembourg Netherlands Poland Portugal Slovakia Spain Sweden United Kingdom (Northern Ireland)

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Combined File of all Documents

eu-puar-frv0315001-mr-rpe537-en.pdf